Artificial Breakthrough of Cell Membrane Barrier for Transmembrane Substance Exchange: A Review of Recent Progress

Abstract

Cell membrane composed of lipid bilayer is a selectively permeable membrane that only allows specific molecules to pass through. While such selectivity is essential for the survival and function of cells, there exist instances when it is necessary to overcome the cell membrane barrier. Study on the artificial cell membrane barrier breakthrough strategies is of great significance for the development of drug delivery systems and the understanding of cellular behaviors. Herein, the advancements in the development of strategies for opening cell membrane barriers over the past decade are summarized. The main transmembrane mechanisms are elucidated and then divided into three categories, i.e., cell perforation via microinjection/external physical fields, cell endocytosis‐assisted construction of artificial transmembrane channels, and untethered micro/nanomachines. Next, the potential applications after opening the cell membrane are discussed, which mainly focus on the transmembrane cargo delivery into the cell and endogenous substance extraction out from the cell. Finally, this review outlines the current challenges that impede the realization of practical applications and presents an outlook of future opportunities to promote further development. Through overcoming the challenges, it is anticipated that artificial cell membrane breakthrough strategies will provide a revolutionized tool in the near future to advance the field of biomedicine and biotechnology.

Steering the course of CAR T cell therapy with lipid nanoparticles

“…This suggests that future investigations should not rely on pH-triggered release for successful transfection. Small size, dynamic membrane properties, and intracellular environment pose challenges in transfecting T cells [ 121 ]. To address these challanges, Ramishetti et al, formulated targeted LNPs by incorporating various designs whereby these LNPs showed specificity by targeting only primary T cells instead of nonimmune cells.…”